RAPT Therapeutics (RAPT)

Data from SEC filings
Employee count
ESG framework mentions
In last year of SEC filings
Sustainability Accounting Standards Board (SASB)
No mentions
Global Reporting Initiative (GRI)
No mentions
Task Force on Climate-related Financial Disclosures (TCFD)
No mentions
UN Sustainable Development Goals (SDGs)
No mentions
Shareholder alignment
Proxy contests and exempt solicitations in last 3 years

No recent proxy contest or exempt solicitation filings from shareholders.

Vote support at last AGM
On May 25, 2022, RAPT Therapeutics, Inc. (the “Company”) held its 2022 annual meeting of stockholders (the “Annual Meeting”). The following is a brief description of each matter voted upon at the Annual Meeting, as well as the number of votes cast for and against each matter, and if applicable, the number of abstentions and broker non-votes with respect to each matter. A more complete description of each matter is described in more detail in the Company’s definitive proxy statement filed with the U.S. Securities and Exchange Commission on April 11, 2022.

1.Election of Directors

Director NameVotes ForVotes
Michael Giordano, MD22,848,9971,545,1211,787,483
Wendye Robbins, MD22,920,5081,473,6101,787,483
The Class III director nominees were elected to hold office until the Company’s 2025 Annual Meeting of Stockholders and until their successors are duly elected and qualified.

2.Ratification of Selection of Independent Registered Public Accounting Firm

FirmVotes ForVotes
Ernst & Young LLP26,178,2931,3701,938
The Company’s stockholders ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2022.